brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

England’s cost effectiveness watchdog says there are limited treatment options for people who have not responded to, or only have a temporary response to, brentuximab vedotin and cannot have stem
Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC
Takeda bags EU approval for Adcetris in lymphoma

CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but
Seattle Genetics' Adcetris earns FDA priority review status

Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS
NICE reverses stance on Takeda’s Adcetris

Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance. ... I am delighted that patients can maintain long term access to Brentuximab

More from news
Approximately 3 fully matching, plus 24 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Project Manager/ Account Manager: Salary TBC

Senior Medical Writer: Salary TBC

Digital Account Director: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Great salary and benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Account Director, Medical Education: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy: Tackling the manufacturing cost and complexity challenges...